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Abstract: Background: Migraine is one of the most disabling neurological conditions and 
associated with high socio-economic costs. Though certain aspects of the pathomechanism of 
migraine are still incompletely understood, the leading hypothesis implicates the role of the 
activation of the trigeminovascular system. Triptans are considered to be the current gold 
standard therapy for migraine attacks; however, their use in clinical practice is limited. Pro-
phylactic treatment includes non-specific approaches for migraine prevention. All these sup-
port the need for future studies in order to develop innovative anti-migraine drugs. 
Objective: The present study is a review of the current literature regarding new therapeutic 
lines in migraine research. 
Method: A systematic literature search in the database of PUBMED was conducted concern-
ing therapeutic strategies in a migraine published until July 2017. 
Results: Ongoing clinical trials with 5-HT1F receptor agonists and glutamate receptor antago-
nists offer promising new aspects for acute migraine treatment. Monoclonal antibodies against 
CGRP and the CGRP receptor are revolutionary in preventive treatment; however, further 
long-term studies are needed to test their tolerability. Preclinical studies show positive results 
with PACAP- and kynurenic acid-related treatments. Other promising therapeutic strategies 
(such as those targeting TRPV1, substance P, NOS, or orexin) have failed to show efficacy in 
clinical trials. 
Conclusion: Due to their side-effects, current therapeutic approaches are not suitable for all 
migraine patients. Especially frequent episodic and chronic migraine represents a therapeutic 
challenge for researchers. Clinical and preclinical studies are needed to untangle the patho-
physiology of migraine in order to develop new and migraine-specific therapies. 
Keywords: Calcitonin gene-related peptide, 5-HT1F receptor agonist, glutamate, pituitary adenylate cyclase-
activating polypeptide, kynurenic acid, trigeminovascular system. 
1. INTRODUCTION 
1.1. Migraine 
Migraine is a severe neurological condition, ranked 
as the sixth most disabling condition of all illnesses and  
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the most disabling condition of neurological diseases, 
based on the results of the Global Burden of Disease 
Study [1]. Clinically, the earliest signs of a migraine 
attack include non-specific premonitory symptoms 
such as tiredness, concentrating difficulty and depres-
sion, symptoms related mainly to the activation of the 
hypothalamus [2]. Visual aura can precede or even ac-
company a headache, represented predominantly by a 
blind or scintillating scotoma [3-4]. Other non-visual 
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auras (e.g., sensory, olfactory, or temporary motor 
symptoms) might also occur [5-6]. In the headache 
phase, the pain is usually unilateral, throbbing, severe 
or moderate in intensity, aggravated by physical activ-
ity, which is often accompanied by nausea, vomiting, 
and photophobia [7]. Postdrome symptoms are consis-
tent with those in the premonitory phase, including 
physical and mental tiredness, depressed mood and 
muscle stiffness [8-9]. 
Despite numerous studies that have tried to shed 
light on the pathomechanism of migraine, several as-
pects are still unclear. The leading hypothesis impli-
cates the role of the activation of the trigeminovascular 
system. Dural perivascular nerve endings that originate 
from the neurons of the trigeminal ganglion (TG) rep-
resent the primary sensory neurons of the pathway. The 
neuronal cell bodies within the TG are surrounded by 
satellite glial cells. The second-order neurons are lo-
cated in the trigeminal nucleus caudalis (TNC) and C1-
C2 region of the spinal cord [10]. They connect pain 
signals to the thalamus and the cerebral cortex [10-11]. 
Structural and functional brain imaging studies have 
revealed a number of other brain areas that become 
activated during migraine attacks, such as the nucleus 
raphe magnus (NRM), the nucleus raphe dorsalis (DG), 
the periaqueductal grey matter (PAG), and the locus 
ceruleus (LC) [12-13]. Structural alterations of the 
brain have been noted in areas involved in pain proc-
essing, such as the anterior cingulate cortex or the tri-
geminal system [14]. The origin of migraine pain is 
still a question of debate. Imaging studies showed no 
vasodilation of intracranial and extracerebral arteries, 
rendering the vascular theory of Wolff obsolete [15]. 
One of the theories postulates that the above mentioned 
brainstem nuclei are responsible for the initiation of 
migraine pain; therefore, they are sometimes referred to 
as ‘migraine generators’. It is still a question whether 
activation of these brain areas generates the pain sensa-
tion or they become activated secondarily. Neurogenic 
inflammation is hypothesized to be an important factor 
in migraine pathophysiology. It is thought to induce a 
state of hyperexcitability, as nociceptive signals are 
transported ortho- and antidromically, leading to the 
release of various cytokines and neuronal messenger 
molecules (such as calcitonin gene-related peptide 
(CGRP), substance P (SP), neuropeptide Y (NPY), and 
nitric oxide (NO)). These molecules are presumed to 
induce the activation of immune cells, mast cells, and 
astrocytes and lead to vascular changes that might 
evoke blood-brain barrier (BBB) dysfunction [16-17]. 
Descending neurons of the CNS might aggravate the  
 
inflammatory responses, resulting in long-term poten-
tiation (LTP) [17-18]. Another phenomenon that has 
been under investigation as an initiating component of 
the migraine pain process is cortical spreading depres-
sion (CSD). CSD is a depolarization wave that moves 
across the cortex from the occipital lobe towards the 
frontal areas, and has been suggested to represent the 
electrophysiological correlate of the aura phase of mi-
graine; however, CSD alone is neither sufficient nor 
necessary to trigger migraine attacks [19-20]. Although 
extensive efforts have been made to elucidate the pos-
sible mechanisms that play pathogenic roles in mi-
graine, certainly much is yet to be unveiled to correctly 
interpret this disease. The most relevant contemporary 
concept postulates that migraine is a neurovascular dis-
order. We hypothesize that pain originates in the cen-
tral nervous system (CNS), resulting in hypersensitivity 
of the perivascular nociceptive afferent nerve fibers, 
which play an essential role in the pathogenesis. 
1.2. Current Treatments in Migraine 
Regarding migraine treatment, analgesics 
(NSAIDs), antiemetics and triptans are the drugs to be 
chosen in the case of a migraine attack. The current 
gold standard therapy is the use of triptans, drugs with 
serotonin receptor (5-HT1B/1D) agonist properties. The 
efficacy of triptans in migraine attacks has been proven 
in large placebo-controlled clinical trials [21]. They 
have proven efficacy in 60% of migraine attacks [22]. 
In clinical practice, the use of triptans has some limita-
tions: clinical trials showed pain relief in only 28-59% 
of the patients [23]. They should be taken in the early 
phase, which leads to frequent drug intake and thus 
increased risk of chronification [24]. Frequent use of 
analgesics or triptans might lead to medication overuse 
headache (MOH). Other important requirements are 
related to the side-effects, to the safety and tolerability 
profiles [25]. One of the most important problems with 
triptans is related to their side effects. Following suma-
triptan therapy, severe cardiovascular adverse events 
(such as stroke, myocardial infarction, and cardiac ar-
rhythmias) have been reported to occur with an inci-
dence of 1:1.000.000 [26-27]. Prophylactic therapy of 
migraine includes beta-adrenergic receptor blockers, 
calcium ion channel blockers, antiepileptic drugs, and 
antidepressants. Chronic migraine represents a thera-
peutic challenge because triptans can be used only 9 
days/month due to high risk of chronification [24]. 
Lately, botulinum toxin A (BoNTA) injected intramus-
cularly into the muscles of face and head has proven to 
be efficient in chronic migraine [28-30].  
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The future goal should be the development of 
migraine-specific drugs with good safety and tolerabil-
ity profile [31]. Due to the individual pain sensation of 
the patients, therapy should aim at personalized medi-
cine. The difficulty of developing new migraine-
specific drugs is represented by the lack of adequate 
animal models and specific biomarkers [25].  
2. NEW THERAPEUTIC TARGETS IN 
MIGRAINE 
In the present article, we have aimed to assess the 
current and novel therapeutic strategies related to dif-
ferent neuropeptides and molecules putatively involved 
in the pathomechanisms of migraine. A systematic lit-
erature review was performed in the database of PUB-
MED until July 2017. We used the following search 
strings: "migraine", "migraine treatment", and "clinical 
studies in migraine". 
2.1. 5-hydroxytryptamine (5-HT, Serotonin) 
5-HT is a metabolite of tryptophan that has proven 
to play a pivotal role in migraine because elevated lev-
els of its metabolite, 5-hydroxyindoleacetic acid (5-
HIAA) were detected early in the plasma of migraine 
patients during attacks [32]. Numerous studies related 
to 5-HT led to the discovery of triptans, which at pre-
sent represent the gold standard therapy in the acute 
treatment. Early studies suggested a vasoconstrictor 
effect on the cranial arteries [33-36]; however, it has 
been demonstrated lately that triptans are not only 
cerebral and dural vasoconstrictors but they also exert 
neuronal effects. Indeed, triptans act on neurogenic 
inflammation in the dura mater [37-38] and they also 
modulate the activity of trigeminal neurons [39]. 5-HT 
receptors represent one of the most complex families of 
neurotransmitter receptors, having seven subfamilies 
and a lot of subtypes. Except for 5-HT3, all forms are 
parts of the G protein-coupled receptor (GPCR) super-
family [40]. Several hundreds of genes encode different 
receptors for neurotransmitters, and post-translational 
modifications result in different proteins [41]. More 
than one hundred cloned orphan GPCRs have so far 
been identified, and it is still unknown how many of 
them belong to the 5-HT receptor family. In an attempt 
to reduce the cardiovascular side effects of triptans, 
researchers focused on finding potent and selective 
ligands for the different receptor subtypes. Sumatriptan 
and naratriptan have been shown to bind with high af-
finity to the 5-HT1F receptor [42], a subtype of the 5-
HT1 receptor class consisting of 366 amino acids and 
having 7 transmembrane domains (TMD) [43-44]. 5-
HT1F receptors have been shown to be expressed in glu-
tamatergic neurons of the trigeminal system and also in 
the cerebral vessels, with no vasoconstrictor effect [45-
46]. The ability of 5-HT1F receptors to modulate tri-
geminal responses without any effect on the vascular 
tone made 5-HT1F agonists promising tools as innova-
tive anti-migraine drugs [47-48]. 4-Fluoro-N-[3-(1-
methyl-4-piperidinyl)-1H-indol-5-yl]-benzamide 
(LY334370) has been shown to be a high-affinity ago-
nist of the 5-HT1F receptor [49]. Among other 5-HT 
receptors, LY334370 shows the next highest affinity 
for 5-HT1A and 5-HT1E, binding only a small fraction of 
these receptors [50]. In preclinical studies, LY334370 
Table 1. Pharmacological data for triptans (source: Tajti et al., 2015). IUPAC- International Union of Pure and Ap-
plied Chemistry, p.o.-per oral, s.c-subcutaneous [25]. 
Drug name Sumatriptan Eletriptan Zolmitriptan Rizatriptan 
Systematic 
(IUPAC) name 
1-[3-(2-
Dimethylaminoethyl)-1H-
indol-5-yl]-N-methyl-
methanesulfonamide 
(R)-3-[(-1-
methylpyrrolidin-2-
yl)merhyl]-5-(2-
phenylsulfonethyl)-1H-
indole 
(S)-4-({3-[2-
(dimetylamino)ethyl]-1H-
indol-5-yl}metyl-1,3-
oxazolidin-2-one 
N,N-dimethyl-2-[5-(1H-
1,2,4-triazol-1-ylmetyl)-
1H-indol-3-
yl]ethanesulfonamide 
Route of ad-
ministration 
p.o., s.c., nasal, rectal, 
transdermal p.o. p.o., nasal p.o. 
Cmax  54 ng/ml (50-100 mg tab-let) 
188-234 ng/ml (80 mg 
tablet) 5.6-9 ng/ml (5mg tablet) 15.7 ng/ml (10 mg tablet) 
Tmax 1.5 h (50-100 mg tablet) 1.8-2.5 h (80 mg tablet) 1.5 h (5mg tablet) 2.3 h (10 mg tablet) 
T1/2 2.3 h (50-100 mg tablet) 4-7 h (80 mg tablet) 2.7 h (5mg tablet) 3.2 (10 mg tablet) 
Metabolism Hepatic-MAO Hepatic-CYP-34A Hepatic-CYP1A2 Hepatic-MAO 
Excretion Renal, fecal Hepatic Renal, fecal Renal, fecal 
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has been proven to block neurogenic inflammation [49] 
and diminished c-fos immunopositivity in the TNC, 
without any vasomotor effect on cerebral vessels [51-
52]. In clinical studies, LY334370 was tested in three 
different doses. The 60 mg and 120 mg doses showed 
superiority over placebo at all three endpoints (2 h re-
sponse, 2 h pain-free, sustained effect) with no cardio-
vascular side effects [53]. Although the study proved 
the efficacy of LY334370 for acute treatment, the stud-
ies were cancelled due to liver toxicity following long-
term use in animal models. 
2,4,6-Trifluoro-N-[6-[(1-methylpiperidin-4-yl)carb-
onyl]pyridin-2yl]benzamide (lasmiditan) represents a 
new generation of 5-HT1F agonists. Lasmiditan does 
not contain the indole core that is present in 5-HT and 
triptans, as the indole core is replaced by a pyridinoyl-
piperidine scaffold. Lasmiditan has higher selectivity to 
the 5-HT1F receptor than LY334370. Following oral 
lasmiditan administration, decreased c-fos activation 
was detected in TNC in a model of electrical stimula-
tion of rat TG and no vasoconstrictive effect was noted 
[54]. Furthermore, lasmiditan, in contrast with triptans, 
can penetrate the BBB, suggesting to be able to act on 
central mechanisms [55]. Phase 1 and phase 2 clinical 
trials have been carried out to test the intravenous and 
oral efficacy of lasmiditan [56-57]. Lasmiditan has 
proven superiority over placebo in the primary end-
point of headache response, with a linear dose-response 
relationship [56]. Oral administration in a dose of 
400 mg showed higher therapeutic gain compared to 
the intravenous dose of 20 mg [57]. The studies show 
rapid absorption and a bioavailability of 40% in the 
case of oral administration [58]. Two ongoing phase 3 
and a long-term open-label trial were started in 2015 to 
test lasmiditan in episodic, disabling migraine [55]. 
Due to its different chemical structure and the selective 
action on the 5-HT1F receptor, the side effects of las-
miditan are completely different from those of triptans. 
Dizziness, paresthesia, and vertigo were the most 
common adverse events reported, predominantly at-
tributable to the presence of 5-HT1F receptors in the 
cerebellum and the vestibular nuclei, and also because 
of the high BBB penetration of lasmiditan [55, 58]. On 
the basis of these, CNS-related side effects can be an-
ticipated following a long-term use of lasmiditan, 
which might limit its clinical use and delay further 
studies [59]. 
NXN-188 is an oral drug developed with a dual 
mechanism of action: acting on neuronal NO synthase 
(nNOS) enzyme and having a high affinity for the 5-
HT1B/1D receptor. Preclinical studies have demonstrated 
the ability of this molecule to inhibit CGRP release in 
animal models using capsaicin or an electrical stimula-
tion of the trigeminovascular system. NXN-188 itself 
did not induce any vasoconstriction in the middle men-
ingeal artery (MMA) but blocked capsaicin-induced 
vasodilation. GR127935, a 5-HT1B/1D receptor antago-
nist was able to block the effect of sumatriptan on the 
MMA and did not influence the effect of NXN-188, 
suggesting that the novel compound acts partially on 
nNOS, being a promising future therapeutic approach 
for migraine prophylaxis [60]. Regarding clinical stud-
ies, five phase 1 trials have been carried out in order to 
test the safety and assess the pharmacokinetics of 
NXN-188 in healthy volunteers. The compound had 
two absorption phases: the first peaked at 1 h, and the 
second at 4-5 h. Initial elimination from the plasma was 
rapid (plasma concentration decreased with 70-90% of 
the Cmax within 24 h) followed by a prolonged elimina-
tion (with 1-5% of the Cmax) for several weeks. NXN-
188 was well tolerated by the participants, the reported 
adverse events were dizziness, headache, and somno-
lence [61]). Unfortunately, phase 2 clinical trials 
showed no statistically significant effect on migraine 
with aura compared to placebo [62]. 
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Fig. (1). Chemical structure of LY-334370 and Lasmiditan. 
2.2. Glutamate (Glu) 
 Glu, the major excitatory neurotransmitter in the 
CNS, has been shown to play crucial roles in the 
pathophysiology of migraine. Elevated levels of Glu 
were detected in the serum of migraine patients [63] 
and in the cerebrospinal fluid (CSF) of patient affected 
by chronic migraine [64]. Glu mediates the CSD phe-
nomenon [65] and has been shown to be co-released 
with CGRP from the neurons of the TG upon activation 
[66]. In animal models of trigeminovascular activation, 
increased Glu activity was detected [67-68]. Glu acts 
on ionotropic and metabotropic receptors as well [69]. 
The ligand-gated ion channels are the N-methyl-D-
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aspartate (NMDA) receptors, the α-amino-3-hydroxí-5-
methyl-4-isoxazelopropionic acid (AMPA) receptors 
and the kainate receptors (that can be divided into sev-
eral subtypes), which mediate fast synaptic transport 
[70]. AMPA receptors have four semiautonomous do-
mains: the amino-terminal domain, the extracellular 
ligand-binding domain (LBD), the TMD, and the intra-
cellular carboxyl-terminal domain (CTD) [70-71]. 
NMDA receptors contain three subunits: NR1 is com-
mon in all cell types; NR2 has four subtypes differen-
tially expressed in different cell types and in various 
CNS structures during certain development processes; 
and NR3 with modulatory function on the receptor. For 
optimal function, both the NR1 and the NR2 subunits 
need to be expressed. The NR1 subunit contains the 
glycine (Gly)-binding site. Gly acts as a coagonist of 
Glu and is essential for the activation of the receptor. In 
inactive form at the resting potential, the channel is 
blocked by Mg2+. Following activation by binding of 
both Glu and Gly to the receptor, Mg2+ dissociates from 
the receptor and opens the channel, resulting in the 
flow of Na+ and Ca2+ into and K+ out of the cell. The 
Ca2+ signal then activates various intracellular path-
ways that lead to exocytotic effects [72-73]. All three 
ionotropic receptors play pivotal roles in migraine, act-
ing on neuronal activation and signal transmission in 
the trigeminal system, but the only receptor linked to 
CSD and thus the aura phenomenon is the NMDA re-
ceptor [74]. Metabotropic Glu receptors (mGluRs) are 
GPCRs and contain at least eight receptor subtypes 
[75]. The N-terminal domain, called Venus Flytrap 
Domain, contains two lobes. The binding of the ligand 
leads to the closure of the two lobes, leading to the ac-
tivation of the receptors [76]. The seven TMD of 
mGluRs is rich in cysteine, which forms disulfide 
bonds in order to increase the stability of the domain 
[77]. The CTD is close to the cell membrane and inter-
acts with signaling pathways [75]. In a small study on 
familial hemiplegic migraine (FHM), intranasal ad-
ministration of ketamine, an NMDA receptor antago-
nist that acts on the Glu-binding site, reduced the inten-
sity and duration of motor symptoms in almost half of 
the patients [78]. In a phase 2 study with migraine pa-
tients suffering from prolonged aura, intranasal keta-
mine was able to reduce the severity of aura but did not 
influence its duration [79]. The AMPA/kainate receptor 
antagonist, tezampanel (LY293558), and a kainate re-
ceptor antagonist, LY 466195, were shown to decrease 
c-fos activity in the rat TNC following electrical stimu-
lation of the TG; whereas the AMPA receptor antago-
nist LY300178 did not influence c-fos activation [80]. 
This leads to the conclusion that the effect of tezam-
panel might be mediated through the kainate rather 
than the AMPA receptor. A phase 2 clinical trial dem-
onstrated that intravenous tezampanel was superior to 
placebo in all endpoints (sustained relief of pain and 
other associated symptoms) and no cardiovascular side 
effects were noted. Adverse events were mainly CNS-
related, including dizziness and somnolence [81]. For 
LY466195, intravenous doses of 1 and 3 mg were 
compared with placebo. The 1 mg dose was not effec-
tive whereas the 3 mg dose showed superiority com-
pared to placebo. As adverse effects, visual distur-
bances were reported in 21% of the patients [82]. ADX 
10059, a negative allosteric modulator of the mGluR5, 
was also tested in phase 2 clinical trials for acute mi-
graine therapy. Following oral administration of ADX 
10059, pain relief was significantly higher than in the 
placebo group at the primary endpoint (2 h), but this 
effect was not proven to be sustained. As side effects, 
dizziness, vertigo, and visual disturbances were re-
ported [74, 83]. All these data suggest that modulation 
of glutamatergic neurotransmission might represent an 
important mechanism for innovative drugs in both the 
acute and the prophylactic treatments of migraine. Fol-
lowing the contemporary concept, kainate receptor an-
tagonist might represent an effective therapeutic mo-
dalities for acute treatment, whereas specific NMDA 
receptor antagonists might be promising therapeutic 
tools for aura phenomena.  
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Fig. (2). Chemical structure of Glu related therapeutic tar-
gets. 
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2.3. Calcitonin Gene-related Peptide (CGRP) 
The pivotal role of CGRP in migraine has been sug-
gested for decades [84-85]. CGRP is a 37-amino-acid 
peptide that has two isoforms, αCGRP and βCGRP, 
with similar chemical structures and biological func-
tions, encoded by two different genes on chromosome 
11 in humans [86]. αCGRP, expressed predominantly 
in the nervous system, is encoded by the CALCI gene 
(together with calcitonin) by means of an alternative 
splicing mechanism. Expression of exons 5 and 6 leads 
to the production of αCGRP mRNA, which is trans-
lated to a prohormone of 121 amino acids and cleaved 
secondarily to yield the mature protein [87]. βCGRP is 
expressed in the enteric nervous system and is tran-
scribed from the CALCII gene [88]. The CGRP recep-
tor is part of the GPCR superfamily and consists of a 7-
TMD, called calcitonin receptor-like receptor (CLR), 
and a single-transmembrane spanning protein, called 
receptor activity-modifying protein 1 (RAMP1), which 
is necessary for the binding of CGRP to the receptor 
[89]. The third component, called receptor component 
protein (RCP), does not affect the binding of CGRP to 
the receptor but it is necessary for signal transduction 
[90]. Previous studies have demonstrated that CGRP is 
a key mediator in migraine, as elevated levels of CGRP 
were found in the plasma, CSF and saliva of migraine 
patients [91-93]. Subsequently, mapping of CGRP and 
its receptors in different structures of the rat and human 
brain demonstrated their role in nociceptive transmis-
sion [94-96]. In animal models of trigeminovascular 
activation, increased CGRP activity was detected [97-
99]. All these findings support a well-established posi-
tion of CGRP in migraine pathophysiology and current 
efforts pursue the identification of potent anti-migraine 
drugs targeting CGRP and its receptors. The most 
comprehensively studied compounds were the ‘gep-
ants’, acting on CGRP receptors. Olcegepant (BIBN 
4096BS, 1-[3,5-Dibromo-N-[[4-(1,4-dihydro-2-oxo-
3(2H)-quinazoline)-1-piperidinyl]carbonyl]-D-tyrosyl-
L-lysyl]-4-(4-pyridyl)-piperazine) was the first CGRP 
receptor antagonist, binding with high selectivity to the 
CGRP receptors. Its relatively high molecular weight 
(Mw = 870 Da) and low oral bioavailability necessi-
tated an intravenous route of administration. In animal 
models, olcegepant has proven to decrease CGRP-
mediated trigeminal activation [100]. In phase 1 clini-
cal study, the maximal concentration was dose-
proportional (Cmax = 0.87 mg/ml), the biological half-
life (T1/2) was 2.5 h and no serious adverse events were 
noted (the most common included fatigue and pares-
thesia) [101]. Although phase 2 clinical trials supported 
the efficacy of olcegepant and, apart from paresthesia, 
no severe adverse events were noted, [102] the intrave-
nous route limited its use in the daily clinical practice 
[103]. Therefore, an oral formula was developed, re-
ferred to as telcagepant (MK-0974, N-((3R,6S)-6-(2,3-
difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-
3-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-
1-yl)piperidine-1-carboxamide). In animal models, tel-
cagepant did not show any effect on the diameter of 
cranial arteries, but blocked the effect of CGRP [104]. 
Human studies showed rapid absorption of telcagepant, 
with a T1/2 of 6 h and Cmax of 0.55 mg/ml. In phase 2 
clinical trials, telcagepant in 300-600-mg doses showed 
superiority to placebo and the same efficacy as zol-
mitriptan (5 mg). Unfortunately, the development of 
telcagepant and its successor, MK-3207, was stopped 
due to liver toxicity and elevated gamma-
glutamyltransferase (GGT) levels developed after long-
term and frequent administration [105]. It has been 
suggested that hepatotoxicity might be a side effect 
related to one of the metabolites of the compounds 
[106]. Rimagepant (BMS-927711, (5S,6S,9R)-5-
amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-
cycloheptapyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-
imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate) 
and BI 44370 TA (4-[[(7R)-8-cyclopentyl-7-ethyl-5-
methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-
(1-methylpiperidin-4-yl)benzamide) have proven effi-
cacy compared to placebo in phase 2 clinical studies 
without any adverse event related to liver toxicity; 
however, the one-dose design of the trials offered lim-
ited information regarding the safety profile in case of 
repeated treatment [107-108]. A newly designed com-
pound, ubrogepant, (MK-1602, (3'S)-N-((3S,5S,6R)-6-
methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperi-
din-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro(cyclopenta(b) 
pyridine-6,3'-pyrrolo(2,3-b)pyridine)-3-carboxamide) 
has recently been developed for acute treatment of mi-
graine and has demonstrated superiority to placebo 
with a good safety and efficacy profile [109]. A phase 
3 clinical study is currently recruiting participants. We 
await further studies providing detailed assessment of 
the tolerability profile during long-term use. 
New classes of biological therapies, monoclonal an-
tibodies acting on CGRP or its receptors have been de-
veloped in recent years. The mechanism of action of 
these molecules is still not fully understood; however, 
they have been shown to prevent repeated activation of 
the trigeminovascular system induced by CGRP, reduc-
ing headache frequency [110]. The pharmacokinetic 
and pharmacodynamic properties of these molecules 
differ completely from those of the gepants. Due to 
their high molecular weight (150 kDa), their instability
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Fig. (3). Chemical structure of CGRP receptor antagonists. 
 
in the gastrointestinal tract, and the low permeability 
through cell membranes, these molecules can only be 
administrated subcutaneously or intravenously. These 
drugs are also not able to cross the BBB [111]. These 
facts collectively lead to the conclusion that these 
molecules act on peripheral targets such as the TG 
[112], as TG was proven to be placed outside the BBB 
[94]. Their plasma half-life is extended to days and 
weeks. This enables longer dosing intervals, which is 
rather favorable in terms of patient compliance [113-
114]. As these molecules are metabolized to small pep-
tides and amino acids, they do not affect hepatic or re-
nal enzymes and the incidence of drug-drug interac-
tions is very low [115]. They are potential immuno-
gens; therefore, they might evoke various immunologi-
cal adverse events such as hypersensitivity, immuno-
suppression or autoimmune processes [116-117]. Al-
though the studies performed with CGRP-related 
monoclonal antibodies have not revealed serious im-
munotoxic effects so far, a small percentage of the pa-
tients were positive for anti-drug antibodies [111]. 
These antibodies are of great importance as they might 
reduce future therapeutic efficacy and might aid the 
development of allergic reactions [111, 118]. Three of 
the monoclonal antibodies tested act on CGRP: 
ALD403 (eptinezumab), TEV-48125 (fremanezumab), 
and LY2951742 (galcanezumab) whereas AMG334 
(erenumab) targets the CGRP receptor. All four anti-
bodies have demonstrated positive effects in migraine 
prevention in phase 1 and phase 2 clinical trials, with 
no significant adverse reactions reported [119-122]. 
TEV-48125 might represent a promising target in 
chronic migraine as well [123]. There are small differ-
ences between the association/dissociation rates of the 
four antibodies that might have an impact on their effi-
cacy: ALD403 attaches to the target twice as rapidly as 
TEV-48125. LY2951742 takes effect as an incomplete 
agonist with fast binding to the target and rapid disso-
ciation [111].  
Primary results of phase 3 clinical trials were pre-
sented on the International Headache Congress 2017 
(IHC 2017), in Vancouver. PROMISE-1 study was de-
signed to evaluate the effect of i.v. eptinezumab in the 
prevention of frequent, episodic migraine. Adult pa-
tients were included, receiving 300mg, 100mg, 30mg 
eptinezumab and placebo. Significant reduction in mi-
graine days was reported in case of eptinezumab, main-
tained at similar levels for long-term (12 weeks). Two 
phase 3 studies (EVOLVE-1 and EVOLVE-2) for s.c. 
use of galcanezumab were performed. Doses of 120mg 
and 240mg were tested and both doses proved superior-
ity for overall mean change in migraine headache days. 
The REGAIN trial was a 3-month study, performed for 
the same doses of s.c. galcanezumab in patients with a 
chronic migraine. Both doses were superior to placebo 
regarding the reduction of migraine headache days. 
Also, treatment with self-administrated galcanezumab 
was proven to be safe and well-tolerated. The STRIVE 
trial was designed to test the effect of s.c. use of 
erenumab, for a dose of 140mg and 70mg. Over 24 
weeks significant reduction was reported in the impact 
of migraine on physical, social and emotional function-
ing of episodic migraine patients (Cephalalgia, Volume 
37, Issue 1_suppl, September 2017). 
Although additional long-term clinical studies are 
needed, it might be reasonably postulated that these 
anti-CGRP monoclonal antibodies represent a new and 
effective therapeutic line in migraine prevention. They 
can be considered revolutionary in the pharmaceutical 
treatment of migraine, especially in case of chronic 
migraine. The only obstacle in their way towards a 
wide clinical use might be their cost/benefit ratio, as 
the cost related to the manufacturing of monoclonal 
antibodies is rather high. It should also be considered, 
however, that migraine is among the priciest neurologi-
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cal diseases in Europe [124] and an effective treatment 
might lead to reduced health care costs. 
3. PROMISING FUTURE THERAPEUTIC TAR-
GETS IN PRECLINICAL PHASE 
3.1. Pituitary Adenylate Cyclase-activating Polypep-
tide (PACAP) 
PACAP is a neuropeptide isolated from the hypo-
thalamus in 1989 [125]. Two bioactive forms of 
PACAP are known: PACAP1-38 and PACAP1-27. 
PACAP1-38 is formed from a precursor (prepro-
PACAP) by convertase enzyme. Two Arg residues are 
split by a carboxypeptidase and the remaining Gly resi-
dues are used to amidate the Lys residue to yield 
PACAP1-38. Another series of Gly Lys Arg of PACAP 
1-38 allows further reactions, providing PACAP1-27 
[126]. The two active forms of PACAP cross the BBB 
in different ways: PACAP1-27 enters via transmem-
brane diffusion attributable to its lipophilic property, 
whereas PACAP1-38 uses a carrier-mediated peptide 
transport mechanism [127]. The role of PACAP1-38 
has been suggested in the ethiopathology of migraine, 
though some aspects are still yet to be revealed [128-
130]. PACAP1-38 was detected in the TG [131], in the 
TNC [132], and also in the parasympathetic otic and 
sphenopalatine ganglia [133-134]. Elevated levels of 
PACAP were found in the interictal phase compared to 
the ictal phase in migraine patients and also in cluster 
headache attacks [135-136]. Intravenous infusion of 
PACAP was able to induce headache in healthy volun-
teers and evoke migraine-like attacks in patients suffer-
ing from migraine without aura [137-138]. Vasoactive 
intestinal peptide (VIP) and PACAP1-38 share the 
same receptors: VPAC1 and VPAC2, whereas PAC1 
has higher affinity for PACAP1-38 [139-140]. The 
vasodilatory effect of PACAP1-38 on dural vessels has 
been proven to be mediated via VPAC2 receptors, 
whereas neurogenic dural vasodilation induced by elec-
trical stimulation of the trigeminal nerve terminals is 
mediated predominantly by PAC1 [138, 141]. Central 
PAC1 receptors are suggested to play key roles in cen-
tral trigeminal activation [142], as PACAP1-38 (but not 
VIP) has been shown to cause delayed sensitization of 
the trigeminal system. In an animal model of dural 
electrical stimulation, a BBB-impermeable PAC1 re-
ceptor antagonist was tested: in the case of peripheral 
administration, the substance was not able to prevent 
neuronal firing of the TNC, whereas the central (i.e. 
intraventricular) administration was able to decrease 
the neuronal activity [141]. To our knowledge, no 
PAC1 receptor antagonists are available that can pene-
trate the BBB. It is a question whether the peripheral 
action of these PAC1 receptor antagonists will prove 
sufficient to prevent migraine attacks or the develop-
ment of novel small molecules will be needed with op-
timized BBB permeability. Another possibility to pre-
vent PACAP1-38-initiated migraine attacks might be 
the use of monoclonal antibodies against PACAP1-38 
per se or against PAC1 receptors, by analogy with 
those developed against CGRP and its receptor [143]. 
It is possible that new molecules are needed to also 
block the central action of PACAP1-38 via the PAC1 
receptor in order to be effective against migraine at-
tacks, whereas peripherally acting substances might be 
used as preventive therapies. Therapeutic strategies 
targeting PAC1 receptor represent promising ap-
proaches for the treatment of migraine, but further pre-
clinical and clinical studies are warranted. 
3.2. Kynurenic Acid (KYNA) 
Tryptophan, one of the essential amino acids, is the 
precursor of 5-HT and L-kynurenine under physiologi-
cal conditions. The kynurenine pathway has been pre-
viously presented in details [128, 144]. Briefly, it is a 
complex metabolic pathway with a lot of neuroactive 
products ending with NAD+ [145]. As these neuroac-
tive metabolites influence NMDA receptor-mediated 
excitotoxicity and the production of free radicals, they 
are presumed to play important roles in various dis-
eases of the CNS [146-150]. KYNA acts on NMDA 
receptors binding to the Gly-binding site of the NR2 
subunit [73] and it also acts on AMPA receptors with a 
dual action: in low concentrations it enhances, whereas 
in higher concentrations it decreases receptor activity 
[151-152]. This leads to the conclusion that modulation 
of the kynurenine pathway might represent an appro-
priate therapeutic tool in migraine treatment and is cur-
rently investigated in preclinical animal studies. As 
KYNA has a very low capacity to cross the BBB, dif-
ferent strategies are needed in order to take advantage 
of its anti-inflammatory and neuroprotective properties. 
One possibility could be the use of a prodrug such as 
L-kynurenine or its derivates [153-155]; whereas shift-
ing the pathway towards the production of KYNA with 
different enzyme inhibitors would represent another 
possible therapeutic strategy [156-157]. During the last 
years, our research group has synthesized several dif-
ferent KYNA derivates that have proven to be effective 
in animal models of cerebral ischemia [158], 
Huntington’s disease [159], epilepsy [160], and rat 
models of trigeminovascular activation [68, 161-162]. 
The chemical structures of these KYNA analogues 
have been previously presented. Briefly, a new cationic 
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center and a water-soluble side-chain were included in 
order to facilitate BBB penetration [163-164].  
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Fig. (4). Chemical structure of different KYNA analogues 
designed by our research group. 
Their exact mechanism of action still needs to be 
untangled. There are two main hypotheses as regards 
their mechanism of action: 1) these molecules might 
act as analogues, mimicking some effects of KYNA, 2) 
they may dissociate into KYNA and serve as a prodrug 
[165-166]. Only a few studies are available to elucidate 
their pharmacokinetic profile. One of these focused on 
two KYNA derivates: N-(2-N,N-dymethylaminoethyl)-
4-oxo-1H-quinoline-2-carboxamide hydrochloride 
(KA-1) and N-(2-N-pyrrolidinylethyl)- 4-oxo-1H-
quinoline-2-carboxamide hydrochloride (KA-2). Fol-
lowing intraperitoneal treatment with these amides, the 
concentrations of KA-1, KA-2 and KYNA were meas-
ured in the rat serum and TNC. The study revealed that 
following intraperitoneal treatment with these amides, 
a sharp increase followed by a sudden decrease in the 
level of KA-1 and KA-2 in the serum could be de-
tected. In the fifth hour, the compounds were still pre-
sent in the serum. Although elevated levels of KYNA 
were found in the serum in the case of both molecules, 
the increase was less for KA-1 than for KA-2. In the 
CNS, only small amount of KA-2 was detected, with 
the level of KA-1 being below the lower limit of detec-
tion [165]. Although these KYNA amides were de-
tected only in trace (or zero) amounts within the CNS, 
animal studies of trigeminovascular activation show 
decreased activation of the TNC following intraperito-
neal treatment with KA1 [68, 167]. There are two po-
tential explanations: 1. the two amids act peripherally, 
metabolized only in small proportion two KYNA, 2. 
the pharmacokinetic studies were performed in intact 
animals. In case of neurogenic inflammation, an impor-
tant phenomenon that occurs during trigeminovascular 
activation causes BBB dysfunction, where the BBB 
becomes penetrable for substances that are normally 
unable to pass [17, 168]. We assume that during mi-
graine attack the BBB dysfunction occurs and pene-
trance of KYNA analogues might be possible but fu-
ture studies are needed to test this hypothesis.  
In summary, all these data suggest that it is neces-
sary to conduct further studies that are needed to en-
lighten the mechanism behind the positive effects of 
the KYNA amides.  
4. FAILED THERAPEUTIC TARGETS 
4.1. Vanilloid Receptor 1 (TRPV1) 
TRPV1 is a non-selective cationic channel, which is 
sensitized and up-regulated during inflammation, play-
ing an important role in noxious stimulatory states 
[169-170]. The efficacy of TRPV1 antagonists in pre-
clinical models of chronic pain has suggested the po-
tential therapeutic benefit of TRPV1 inhibition in this 
condition [171]. In case of migraine, animal studies 
provided contradictory results: a TRPV1 antagonist 
was ineffective in two different animal models [172], 
whereas another TRPV1 antagonist was proven to be 
effective in an animal model of electrical and mechani-
cal stimulation of the dura mater in cats [173]. In vitro 
pharmacological studies suggested that SB-70498 had 
the best pharmacological properties among the TRPV1 
receptor antagonists. Its metabolic stability and a 
bioavailability of almost 86% made SB-70498 a prom-
ising molecule for clinical studies [174]. However, 
phase 2 clinical studies were terminated early as SB-
70498 did not show any superiority to placebo in acute 
migraine treatment [175]. These findings do not sup-
port the use of TRPV1 antagonists in the treatment of 
migraine. 
4.2. Substance P (SP) 
SP was shown to be expressed in various parts of 
the CNS and has been implicated in the pathophysiol-
ogy of migraine [176]. SP acts on the tachykinin recep-
tors (NK1, NK2, and NK3), predominantly on NK1. The 
SP receptor antagonist, PRP100893, has proven to di-
minish plasma protein extravasation following electri-
cal stimulation of the TG in guinea pigs [177]. Unfor-
tunately, phase 2 clinical studies did not support the 
efficacy of SP receptor antagonist in acute migraine 
attacks [178]. Lanepitant, another NK1 receptor an-
tagonist that showed promising results in preclinical 
studies, was not proven to be efficient in migraine pre-
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vention [179]. The above-mentioned data suggest that 
therapeutic strategies targeting SP or its receptors 
might not be adequate for acute or prophylactic mi-
graine treatment.  
4.3. Nitric Oxide (NO.) 
NO. is a labile gas, produced by three iso-enzymes 
called NOSs: neuronal (nNOS) inducible NOS (iNOS) 
and endothelial NOS (eNOS), which have been impli-
cated in migraine pathophysiology [180]. 
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Fig. (5). Synthesis of NO. by NOS. 
 Indeed, NOS-immunopositive neurons were de-
tected in the TG [131]. Due to the possible vascular 
side effects via eNOS, the focus has been put on phar-
macological studies targeting iNOS or nNOS [181-
182]. In clinical studies, no superiority to placebo was 
noted either as acute or as a prophylactic treatment in 
migraine [183]. A selective iNOS inhibitor and 5-
HT1B/1D receptor agonist has also been assessed, reveal-
ing no clinical efficacy. The studies concluded that any 
future therapeutic approach related to NO. synthesis 
should be handled with dubitation [168]. 
4.4. Orexin 
The orexin (hypocretin) system is a family of hypo-
thalamic neuropeptides [184] playing a key role in the 
regulation of sleep and wakefulness [185]. Recent find-
ings have supported the role of orexins in nociception 
and in migraine as well, as in preclinical studies, orexin 
receptor antagonists were able to diminish TNC activa-
tion following electrical stimulation of dural blood ves-
sels in rat [186]. In phase 2 clinical study, the efficacy 
of a dual orexin receptor antagonist (MK-6096, 
filorexant) was tested as prophylactic treatment. This 
study did not show any evidence supporting the effi-
cacy of filorexant as it was not superior to placebo. 
Adverse events (including fatigue and somnolence) 
were more common for filorexant treatment than in 
placebo. It can be presumed that the unfavorable phar-
macological profile of the drug (i.e., rapid Tmax and 
short half-life) might be attributable for the negative 
results [187]. To our knowledge, no clinical trials are 
ongoing in relation to orexin or its receptors. 
CONCLUSION 
Taken together, we conclude that currently available 
clinical and preclinical data provide promising thera-
peutic targets and tools for future migraine therapies. It 
is unquestionable that migraine has a high impact on 
individual and public health. Besides the well-
established role of the trigeminovascular system in mi-
graine pathogenesis, the involvement of other brain 
centers and phenomena such as CSD or neurogenic 
inflammation have become more and more established. 
All these demonstrate that much is yet to be unveiled to 
sufficiently understand the mechanisms regarding the 
generation of a migraine attack. Except for triptans, all 
other groups of drugs currently used in the daily prac-
tice are not migraine-specific. As CGRP has proven to 
be a key mediator in migraine, it has become the most 
promising target for new therapeutic approaches. After 
the disappointing side effects of telcagepant, the mono-
clonal antibodies against CGRP can bring a revolution 
in the preventive treatment of migraine. We hope that 
the high production costs of these antibodies will not 
limit their everyday use in the clinical practice. Pre-
liminary data of several phase 3 studies presented on 
the IHC 2017 are extremely promising. 
The selective targeting of the 5-HT1F receptor might 
overcome the cardiovascular side effects associated 
with triptans, making lasmiditan a highly promising 
drug in the future in migraine attack therapy. Glu-
related treatments also seem to be effective in acute 
and preventive treatments of migraine. However, it 
should be taken into consideration that Glu is 
ubiquitous in the CNS; therefore possible CNS-related 
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side effects might limit the use of these medications in 
the daily practice. 
It is still a question of debate whether a peripheral 
site of action per se is sufficient for migraine treatment 
or an effective substance will need to cross the BBB as 
well. We assume that the peripheral site of action (pre-
dominantly on the TG) might be effective for migraine 
prevention. To prevent central sensitization, penetra-
tion through the BBB is, however, indispensable. The 
antagonism of PACAP-mediated effects and the 
KYNA-mediated anti-glutamatergic mechanisms might 
be promising therapeutic approaches, as suggested by 
preclinical animal studies. Future research should focus 
on elucidating the pharmacodynamics of PAC1 an-
tagonists and KYNA analogues. The limitations of pre-
clinical studies need to be emphasized, however, as a 
number of molecules previously considered effective in 
animal models were not able to show efficacy in phase 
2 clinical trials. 
All these support the need of further studies both at 
the clinical and pre-clinical levels in order to shed light 
on the ethiopathology of migraine, opening novel lines 
of therapeutic strategies in this highly disabling neuro-
logical condition. 
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